The FDA has approved two new drugs, bimatoprost ophthalmic solution, 0.03% (Lumigan, Allergan Inc, Irvine, Calif), and travoprost ophthalmic solution, 0.004% (Travatan, Alcon Universal Ltd, Fort Worth, Tex), for reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Both products provide additional alternatives for patients who are intolerant of other IOP-lowering medications or insufficiently responsive (failure to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.
Schwetz BA. Two Ophthalmic Solutions. JAMA. 2001;285(17):2186. doi:10.1001/jama.285.17.2186-JFD10004-2-1